Ethyl 4-Formyl-1H-Pyrrole-2-Carboxylate

Ethyl 4‑formyl‑1H‑pyrrole‑2‑carboxylate participates in a tightly controlled processing window during the Adler–Longo synthesis of asymmetric meso-substituted porphyrins, where the aldehyde group’s reactivity must be balanced against competing oligomerisation. In a 500 L glass‑lined reactor equipped with a reflux condenser and a retreat‑curve impeller, a solution of 4.0 molar parts freshly distilled pyrrole, 3.0 molar parts benzaldehyde, and 1.0 molar part of the pyrrole ester‑aldehyde in propionic acid (reactant concentration 0.25 M total pyrrole) is heated to 141 ± 2 °C under atmospheric pressure. Deviation of the jacket temperature beyond this 2 °C band causes a sharp drop in the yield of the target A₃B‑type porphyrin—from 12–15 % to below 3 %—as linear polypyrromethanes become the dominant species, a failure mode observable within 45 minutes as the reaction mass turns from deep amber to a viscous tarry consistency. Post‑reaction quenching into ice‑cold methanol precipitates the crude porphyrin, which is washed with methanol‑water (3:1 v/v) and dried in a vacuum shelf dryer at 80 °C for 24 h. The isolated 5‑(4‑ethoxycarbonylphenyl)‑10,15,20‑triphenylporphyrin is subsequently hydrolysed to the free carboxylic acid and purified by column chromatography (silica gel, chloroform/methanol) to a purity of ≥98 % (HPLC, USP <621>). The final porphyrin derivative serves as a photosensitiser in photodynamic therapy formulations and as a building block for metal‑organic frameworks used in singlet‑oxygen generation. Compliance for residual propionic acid and process‑related impurities follows USP <467> and ICH Q3C guidance for Class 3 solvents; endotoxin limits are verified per USP <85> when the product is destined for parenteral investigational medicinal products.

What governs the diastereoselectivity of the Knoevenagel adduct with 1,3‑indanedione?

When Ethyl 4‑formyl‑1H‑pyrrole‑2‑carboxylate is condensed with 1.05 molar equivalents of 1,3‑indanedione in toluene in the presence of 0.1 molar equivalents of piperidinium acetate, the reaction proceeds through a Dean–Stark trap to remove water continuously. The bulk liquor temperature is maintained at 110–112 °C; excursions above 115 °C induce a Z‑to‑E isomerisation at the exocyclic double bond, reducing the pharmacologically active Z‑isomer content to less than 40 % as determined by ¹H‑NMR integration of the vinyl proton signals. The 20 L jacketed borosilicate reactor is charged under nitrogen, and the addition rate of the aldehyde—dissolved in dry toluene and metered over 60 min—is regulated to avoid localised exotherms that generate an intractable brown gum on the vessel walls. After 5 h of reflux, the solvent is stripped under reduced pressure (50 mbar, 45 °C) and the crude product is recrystallised from ethanol‑water (7:3) to afford the desired 2‑((5‑(ethoxycarbonyl)‑1H‑pyrrol‑3‑yl)methylene)‑1H‑indene‑1,3(2H)‑dione as a single geometric isomer. The compound is an intermediate in the synthesis of non‑steroidal androgen receptor antagonists and has been scaled to multi‑kilogram campaigns under cGMP conditions compliant with ICH Q7. Mutagenic impurity control follows ICH M7 classification, and a purge factor calculation using the Teasdale method confirms that the aldehyde‑derived impurity is purged below the threshold of toxicological concern.

Under strictly anhydrous conditions, a DMF solution of Ethyl 4‑formyl‑1H‑pyrrole‑2‑carboxylate is metered into a slurry of NH₂‑functionalised UiO‑66(Zr) at a ligand‑to‑aldehyde stoichiometry of 1:1.2. The post‑synthetic modification is conducted in a 100 mL Parr high‑pressure reactor with a PTFE liner, stirred at 300 rpm and heated to 90 °C for 24 h. Excess aldehyde and the Schiff‑base by‑product are removed by three cycles of centrifuging at 10 000 rpm and redispersing in fresh DMF, followed by solvent exchange with methanol and activation under dynamic vacuum at 120 °C for 18 h. The imine‑functionalised MOF retains a BET surface area of 1 200 ± 50 m²/g (ISO 9277:2022) and is employed as a recyclable heterogeneous catalyst for Knoevenagel condensations under continuous‑flow conditions. The catalytic bed, packed in a stainless‑steel column (4.6 mm i.d. × 150 mm), is operated at a back‑pressure of 30 bar and a liquid hourly space velocity of 0.5 h⁻¹. Quality assurance for the starting MOF is conducted under an ISO 9001:2015‑certified management system, and residual solvent levels are controlled according to the pharmacopoeial thresholds of USP <467> when the catalyst is intended for API‑grade organic transformations.

Controlling charge‑transfer band energy in a pyrrole‑derived D–π–A chromophore for dye‑sensitised solar cells

A Knoevenagel condensation between the pyrrole‑aldehyde and 2.2 molar equivalents of cyanoacetic acid is performed in a single‑mode microwave reactor (Biotage Initiator+) at 150 °C and a constant irradiation power of 150 W for 30 min, using a 10:1 v/v acetonitrile‑triethylamine mixture as solvent. Precise control of absorbed power is critical: lowering the power to 100 W leaves 15–20 % unreacted aldehyde, while increasing it to 200 W generates a decarboxylated by‑product that co‑elutes with the target dye on reverse‑phase HPLC (Agilent ZORBAX Eclipse Plus C18, 4.6×250 mm, 5 µm). The crude dye is purified by flash chromatography, and the isolated 2‑cyano‑3‑(5‑(ethoxycarbonyl)‑1H‑pyrrol‑3‑yl)acrylic acid is adsorbed onto a 6 µm‑thick TiO₂ photoanode from a 0.3 mM ethanol solution containing 0.1 mM chenodeoxycholic acid. Current‑voltage characteristics measured under AM 1.5G illumination (100 mW/cm²) in accordance with IEC 60904‑1:2020 yield a short‑circuit current density of 12.5 mA/cm² and a power conversion efficiency of 6.2 % with an iodine‑based redox electrolyte. The ester moiety remains intact in the final dye formulation to improve solubility during coating and to shift the conduction band edge of TiO₂ by –80 mV, as determined by Mott–Schottky analysis. Photovoltaic modules assembled with this dye comply with IEC 61215‑1‑1:2021 for design qualification and type approval.

Condensation of Ethyl 4‑formyl‑1H‑pyrrole‑2‑carboxylate with (R,R)‑1,2‑diaminocyclohexane in a molar ratio of 2:1 in refluxing anhydrous ethanol containing 0.5 mol% p‑toluenesulfonic acid proceeds in a 50 L jacketed stainless‑steel reactor under a nitrogen blanket. The dosed aldehyde solution is pre‑dried over activated 4 Å molecular sieves to a water content below 500 ppm (Karl Fischer titration, ASTM E203‑23); higher moisture levels lead to hydrate formation on the aldehyde and a sluggish reaction that plateaus at 70 % conversion after 8 h. After 5 h at 78 °C, the pale‑yellow precipitate is filtered under suction, washed with cold ethanol, and dried under vacuum to yield the chiral diiminopyrrole ligand in 92 % purity, suitable for complexation with copper(II) acetate without further purification. The resulting copper–salen‑type complex catalyses the asymmetric Henry reaction between nitromethane and benzaldehyde with an enantiomeric excess of 94 % (chiral HPLC, Chiralpak IA), a turnover frequency of 120 h⁻¹, and sustained activity over five consecutive runs in a continuous stirred‑tank reactor. The manufacturing process of the ligand itself adheres to the environmental and safety obligations of REACH Regulation (EC) No 1907/2006 and is audited under an ISO 14001:2015‑registered environmental management system.

Exploiting the aldehyde for reductive amination in fluorescence polarisation immunoassay tracer synthesis

Phosphate‑buffered saline (pH 9.5) is degassed and charged into a 5 L jacketed reactor, to which bovine serum albumin (50 g, 0.75 mmol) is added and dissolved by gentle overhead stirring at 40 rpm. A freshly prepared solution of Ethyl 4‑formyl‑1H‑pyrrole‑2‑carboxylate (10‑fold molar excess relative to lysine ε‑amino groups) in DMSO is introduced dropwise, followed by the portionwise addition of sodium cyanoborohydride to a final concentration of 50 mM. The reductive amination proceeds for 16 h at 4 °C in the dark; residual aldehyde is quenched with an aqueous glycine solution, and the conjugate is purified by size‑exclusion chromatography on a Sephadex G‑25 column (2.6 cm × 30 cm) equilibrated with PBS, pH 7.4. The degree of labelling, determined spectrophotometrically at the absorption maximum of 282 nm (molar extinction coefficient 18 500 M⁻¹·cm⁻¹), is typically 8–12 fluorophore molecules per BSA monomer. The labelled protein serves as a tracer in a competitive fluorescence polarisation assay for the detection of small‑molecule drugs in human serum, with a limit of detection of 0.5 ng/mL. All reagents and intermediates used in the conjugation are manufactured under a quality system compliant with ISO 13485:2016, and the final conjugate is tested for bioburden per USP <61> and for endotoxins per USP <85> prior to release as a critical IVD raw material.